This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Les Entreprises du Médicament | |
|---|---|
| Name | Les Entreprises du Médicament |
| Native name | Les Entreprises du Médicament |
| Formation | 20th century |
| Type | Trade association |
| Headquarters | Paris, France |
| Region served | France |
| Membership | Pharmaceutical companies |
| Language | French |
Les Entreprises du Médicament is a French trade association representing pharmaceutical companies operating in France, serving as an interlocutor with national and European institutions and industry stakeholders. It articulates positions on healthcare regulation, market access, pricing, and research incentives while engaging with international organisations and academic partners. The organisation interacts with regulatory bodies, patient groups, and corporate members to influence policy and coordinate industry responses to public health challenges.
The association presents itself as a collective voice for firms active in the pharmaceutical sector, liaising with institutions such as Ministry of Health (France), European Commission, World Health Organization, and Organisation for Economic Co-operation and Development to defend industry positions. Its stated mission includes promoting innovation, ensuring patient access to medicines, and supporting frameworks similar to those discussed by European Medicines Agency and International Federation of Pharmaceutical Manufacturers & Associations. It engages with stakeholders like Haute Autorité de Santé, Cour des comptes (France), Agence nationale de sécurité du médicament et des produits de santé to address reimbursement, safety, and transparency topics.
Founded in the 20th century amid consolidation of trade groups, the organisation evolved alongside peers such as British Pharmaceutical Industry Federation, Pharmaceutical Research and Manufacturers of America, and Bundesverband der Pharmazeutischen Industrie. Its development tracks major events including regulatory shifts after the Thalidomide scandal, the creation of European Medicines Agency, and policy changes following the Horizon 2020 programme and European Green Deal. It adapted during crises referenced in the context of SARS-CoV-2 pandemic, aligning with industry initiatives led by entities like Gavi, the Vaccine Alliance and Coalition for Epidemic Preparedness Innovations.
Governance combines an executive board, a president drawn from major member firms such as multinational corporations headquartered in regions like Île-de-France and corporate counsel influenced by legal frameworks exemplified by Code de la santé publique (France). Membership encompasses multinational companies analogous to Sanofi, Roche, Pfizer, Novartis and domestic firms comparable to Ipsen and Servier, alongside smaller biotech companies similar to Genfit or contract organisations echoing IQVIA. The organisation engages with umbrella groups including European Federation of Pharmaceutical Industries and Associations and national chambers like Medef.
Activities include advocacy on pricing and reimbursement models reflected in debates involving Caisse nationale d'assurance maladie, work on intellectual property issues related to the Agreement on Trade-Related Aspects of Intellectual Property Rights, and participation in public–private partnerships mirroring collaborations with Inserm, CNRS, and universities such as Sorbonne University. It provides position papers on pharmaceutical manufacturing, supply chain resilience linked to actors like Port of Marseille-Fos and logistics firms, and contributes to discussions on clinical trial regulation in the spirit of Clinical Trials Regulation (EU) No 536/2014.
The association highlights the sector’s contributions to employment across regions including Auvergne-Rhône-Alpes and Hauts-de-France, investment patterns similar to those reported by Invest in France Agency, and export activity tied to markets such as Germany, United Kingdom, and United States. It underscores links to industrial policy instruments exemplified by Plan d'investissement pour la France and research funding mechanisms like European Research Council grants to illustrate economic impact and value chain significance.
The organisation engages with national and European regulators including Ministry of Economy and Finance (France), European Parliament, and agencies such as ANSM to shape regulation on market access, pharmacovigilance, and public procurement. It participates in consultations related to legislation comparable to Loi Huriet-Sérusclat and policy reforms influenced by rulings from bodies like Conseil d'État (France) and deliberations within committees of the Council of the European Union.
Critiques directed at the association echo controversies involving industry lobbies worldwide, including disputes over pricing strategies similar to those seen with Valeant Pharmaceuticals International, concerns about transparency paralleling debates around GlaxoSmithKline settlements, and tensions on intellectual property raised in dialogues involving Médecins Sans Frontières and Access to Medicine Foundation. Critics cite potential conflicts of interest akin to cases examined by Transparency International and contested interactions with health technology assessment bodies such as NICE and HAS.
The organisation promotes research partnerships with academic centres like Institut Pasteur and Collège de France, supports innovation-friendly policies reminiscent of Startup Nation frameworks, and endorses corporate social responsibility programs aligned with standards from United Nations Global Compact and Global Reporting Initiative. It advances initiatives on sustainable manufacturing comparable to commitments under Science Based Targets initiative and collaborates on access programs that echo models from UNICEF vaccine distribution efforts.
Category:Pharmaceutical industry organizations Category:Trade associations based in France